Ascelia Pharma recently announced its maiden interim financial results as a public company. Q319 operational expenditure and net loss has increased versus Q318 due to the Phase III study preparation and IPO costs. It is interesting to see a company with a clinical pipeline appear on the public market. Ascelia’s first product is Phase III ready with a sophisticated regulatory strategy.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Ascelia Pharma
Ascelia Pharma recently announced its maiden interim financial results as a public company. Q319 operational expenditure and net loss has increased versus Q318 due to the Phase III study preparation and IPO costs. It is interesting to see a company with a clinical pipeline appear on the public market. Ascelia’s first product is Phase III ready with a sophisticated regulatory strategy.